An interventional study of Norepinephrine and Phenylephrine in Adverse Event and Hypotension (MeSH: D007022), sponsored by General Hospital of Ningxia Medical University. Not yet recruiting. Open to female participants aged 35 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment
This study aims to estimate the 90% effective dose (ED₉₀) of norepinephrine and phenylephrine infusions for the prevention of maternal hypotension in patients of advanced maternal age undergoing cesarean section, using the sequential allocation method.
The proportion of pregnancies involving advanced maternal age has been increasing annually, and advanced maternal age itself is an independent high-risk factor for maternal hypotension following spinal anesthesia for cesarean delivery. Therefore, theoretically, the demand for vasopressors during spinal anesthesia in advanced maternal age patients should be higher. This study aims to estimate the 90% effective dose (ED₉₀) of norepinephrine and phenylephrine infusions for the prevention of maternal hypotension in patients of advanced maternal age undergoing cesarean section, using the sequential allocation method.
1,023 studies on the registry are indexed under Hypotension; 172 are open to participants now.
This study's planned enrollment of 60 is below the median of 80 across 686 interventional studies indexed under Hypotension.
Browse Hypotension studies →General Hospital of Ningxia Medical University is the lead sponsor of 108 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Drug: Norepinephrine
The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Drug: Phenylephrine
An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up down sequential allocation.
An initial infusion dose of prophylactic norepinephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up down sequential allocation.
ED90
The ED90 of norepinephrine and phenylephrine infusion for prevention of maternal hypotension under spinal anesthesia
Time frame: 1-15 minutes after spinal anesthesia
The incidence of post-spinal anesthesia hypotension
Systolic blood pressure (SBP) \< 80% of the baseline
Time frame: 1-15 minutes after spinal anesthesia.
The incidence of severe post-spinal anesthesia hypotension.
Systolic blood pressure (SBP) \< 60% of the baseline
Time frame: 1-15 minutes after spinal anesthesia.
pH
From umbilical arterial blood gases.
Time frame: Immediately after delivery
APGAR score
A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration
Time frame: 1 minute after delivery
APGAR score
A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration
Time frame: 5 minute after delivery
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2027, 0 months later.
Of 237 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 25. This study's planned 0 months is below that.
Counting every sponsor, half of 248 studies reached it within 12 months; a quarter within 6 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Norepinephrine · Phenylephrine
General Hospital of Ningxia Medical University →